A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
Introduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases. Methods: 20 patients who had been diagnosed wit...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2010-03-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233 |
id |
doaj-c06d92e0679a49cda5103f7cf3fcb6c1 |
---|---|
record_format |
Article |
spelling |
doaj-c06d92e0679a49cda5103f7cf3fcb6c12020-11-25T03:59:14ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072010-03-0141A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute LeukemiaReza Safaei Nodehi0Behrouz Gharib1Ramazaali Sharifian2Amirhossein Emami3Majid Moghadaszadeh4Sara Sardashti5Tehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTehran University of Medical Sciences- Hematology and Oncology residentTehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTabriz Azad University of Medical Sciences-Tabriz Young Researchers ClubTabriz University of Medical SciencesIntroduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases. Methods: 20 patients who had been diagnosed with acute leukemia and who had displayed defined criteria in order to enter our study, were assessed in a clinical trial. A combined chemotherapy regimen with Cladribine and Cytarabine was used in the evaluation of the response to treatment and other parameters between the two ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia) groups. Results: Average patient age was 32.5±11.3. 13 patients (65%) were male and 7 patients (35%) were female. The average blast count was 67.7% ±18.3% in the AML group while this count was 63.8±19.6% in the ALL group. 5 out of 11 (45.5%) AML patients and 4 out of 9 ALL patients (44.4%) died during our experiment with no significant statistical difference between the two groups (P=0.65). 4 of the AML patients (36.4%) showed complete response while 4 cases (36.4%) were refractory. In the ALL group, there were 3 patients (33.3%) with complete response and 5 (55.6%) were refractory cases. Conclusion: According to the results of the present study compared to other similar studies, a combined chemotherapy regimen of Cladribine and Cytarabine can be used in acute relapsed and refractory leukemia, however, with high toxicity and high early mortality. If factors are controlled, mortality can be reduced in some cases. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233Acute LeukemiaChemotherapy RegimenMortality |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Reza Safaei Nodehi Behrouz Gharib Ramazaali Sharifian Amirhossein Emami Majid Moghadaszadeh Sara Sardashti |
spellingShingle |
Reza Safaei Nodehi Behrouz Gharib Ramazaali Sharifian Amirhossein Emami Majid Moghadaszadeh Sara Sardashti A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia International Journal of Hematology-Oncology and Stem Cell Research Acute Leukemia Chemotherapy Regimen Mortality |
author_facet |
Reza Safaei Nodehi Behrouz Gharib Ramazaali Sharifian Amirhossein Emami Majid Moghadaszadeh Sara Sardashti |
author_sort |
Reza Safaei Nodehi |
title |
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia |
title_short |
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia |
title_full |
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia |
title_fullStr |
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia |
title_full_unstemmed |
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia |
title_sort |
study of the complete response rate with a combination of high dose cytarabine and cladribine in refractory and relapsed acute leukemia |
publisher |
Tehran University of Medical Sciences |
series |
International Journal of Hematology-Oncology and Stem Cell Research |
issn |
2008-2207 |
publishDate |
2010-03-01 |
description |
Introduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases.
Methods: 20 patients who had been diagnosed with acute leukemia and who had displayed defined criteria in order to enter our study, were assessed in a clinical trial. A combined chemotherapy regimen with Cladribine and Cytarabine was used in the evaluation of the response to treatment and other parameters between the two ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia) groups.
Results: Average patient age was 32.5±11.3. 13 patients (65%) were male and 7 patients (35%) were female. The average blast count was 67.7% ±18.3% in the AML group while this count was 63.8±19.6% in the ALL group. 5 out of 11 (45.5%) AML patients and 4 out of 9 ALL patients (44.4%) died during our experiment with no significant statistical difference between the two groups (P=0.65). 4 of the AML patients (36.4%) showed complete response while 4 cases (36.4%) were refractory. In the ALL group, there were 3 patients (33.3%) with complete response and 5 (55.6%) were refractory cases.
Conclusion: According to the results of the present study compared to other similar studies, a combined chemotherapy regimen of Cladribine and Cytarabine can be used in acute relapsed and refractory leukemia, however, with high toxicity and high early mortality. If factors are controlled, mortality can be reduced in some cases.
|
topic |
Acute Leukemia Chemotherapy Regimen Mortality |
url |
https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233 |
work_keys_str_mv |
AT rezasafaeinodehi astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT behrouzgharib astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT ramazaalisharifian astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT amirhosseinemami astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT majidmoghadaszadeh astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT sarasardashti astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT rezasafaeinodehi studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT behrouzgharib studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT ramazaalisharifian studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT amirhosseinemami studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT majidmoghadaszadeh studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia AT sarasardashti studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia |
_version_ |
1724455077187420160 |